Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making.

Weiss GJ, Hoff BR, Whitehead RP, Sangal A, Gingrich SA, Penny RJ, Mallery DW, Morris SM, Thompson EJ, Loesch DM, Khemka V.

Onco Targets Ther. 2015 Apr 24;8:959-67. doi: 10.2147/OTT.S81995. eCollection 2015.

2.

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).

Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blanke CD.

Cancer. 2014 Oct 1;120(19):2980-5. doi: 10.1002/cncr.28744. Epub 2014 Jul 16.

3.

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).

Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL, Blanke CD.

Invest New Drugs. 2009 Oct;27(5):469-75. doi: 10.1007/s10637-008-9190-8. Epub 2008 Oct 22.

4.

A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.

Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL.

Invest New Drugs. 2006 Nov;24(6):515-20.

PMID:
16699973
5.

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.

Whitehead RP, McCoy S, Macdonald JS, Rivkin SE, Neubauer MA, Dakhil SR, Lenz HJ, Tanaka MS, Abbruzzese JL; Southwest Oncology Group.

Invest New Drugs. 2006 Jul;24(4):335-41.

PMID:
16683076
7.

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.

Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL 3rd, Giguere JK, Abbruzzese JL.

Invest New Drugs. 2005 Oct;23(5):485-7.

PMID:
16133800
8.

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Whitehead RP, Benedetti JK, Abbruzzese JL, Ardalan B, Williamson S, Gaynor ER, Balcerzak SP, Macdonald JS.

Invest New Drugs. 2004 Nov;22(4):467-73.

PMID:
15292717
9.

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.

Whitehead RP, Benedetti JK, Abbruzzese JL, Ardalan B, Goodwin JW, Balcerzak SP, Samlowski WE, Lenz HJ, Macdonald JS.

Invest New Drugs. 2004 Aug;22(3):335-41.

PMID:
15122082
10.

A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.

Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK; Southwest Oncology Group.

Cancer. 2004 Apr 15;100(8):1699-704.

11.

Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study.

Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED.

J Immunother. 2002 Jul-Aug;25(4):352-8.

PMID:
12142558
12.

A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.

Whitehead RP, Unger JM, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK; Southwest Oncology Group.

Invest New Drugs. 2002 Feb;20(1):105-11.

13.
14.

Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.

Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK.

Invest New Drugs. 2001;19(3):239-43.

15.

Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study.

Whitehead RP, Unger JM, Goodwin JW, Walker MJ, Thompson JA, Flaherty LE, Sondak VK.

J Immunother. 1998 Nov;21(6):440-6.

PMID:
9807739
16.

Secondary syringomyelia due to intramedullary spinal cord metastasis. Case report and review of literature.

Keung YK, Cobos E, Whitehead RP, Roberson GH.

Am J Clin Oncol. 1997 Dec;20(6):577-9. Review.

PMID:
9391544
17.

Double minute chromosomes and myelodysplastic syndrome: a case report and literature review.

Keung YK, Cobos E, Morgan D, Whitehead RP, Tonk V.

Cancer Genet Cytogenet. 1997 Sep;97(2):94-6. Review.

PMID:
9283588
18.

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.

Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS.

J Clin Oncol. 1997 Jun;15(6):2414-9.

PMID:
9196157
19.

Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer--review of literature.

Keung YK, Whitehead RP, Cobos E.

Gynecol Oncol. 1996 Jun;61(3):448-50. Review.

PMID:
8641632
20.

Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.

Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L.

Clin Cancer Res. 1995 Oct;1(10):1145-52.

21.

A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.

Whitehead RP, Wolf MK, Solanki DL, Hemstreet GP 3rd, Benedetto P, Richman SP, Flanigan RC, Crawford ED.

J Immunother Emphasis Tumor Immunol. 1995 Aug;18(2):104-14.

PMID:
8574465
22.

Diabetes mellitus in cancer patients treated with combination interleukin 2 and alpha-interferon.

Whitehead RP, Hauschild A, Christophers E, Figlin R.

Cancer Biother. 1995 Spring;10(1):45-51.

PMID:
7780486
23.

Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.

Kuebler JP, Whitehead RP, Ward DL, Hemstreet GP 3rd, Bradley EC.

J Urol. 1993 Sep;150(3):814-20. Review.

PMID:
8345590
24.

A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma.

Whitehead RP, Figlin R, Citron ML, Pfile J, Moldawer N, Patel D, Jones G, Levitt D, Zeffren J.

J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):117-21.

PMID:
8318496
25.

A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.

Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart JA, Gonzalez R, Bunn PA, Hersh EM.

J Immunother (1991). 1992 Apr;11(3):176-83.

PMID:
1515422
26.

Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience.

Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, Bonnet JD, Behrens BC.

J Immunother (1991). 1991 Dec;10(6):426-31.

PMID:
1768676
27.

A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.

Whitehead RP, Fleming TR, Macdonald JS, Ahmann FR, Garewal HS, Kuebler JP.

Invest New Drugs. 1991 Nov;9(4):345-7.

PMID:
1804811
28.

Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study.

Whitehead RP, Kopecky KJ, Samson MK, Costanzi JJ, Natale RB, Feun LG, Hersh EM, Rinehart JJ.

J Natl Cancer Inst. 1991 Sep 4;83(17):1250-2. No abstract available.

PMID:
1870152
29.

A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.

Whitehead RP, Fleming T, Macdonald JS, Goodman PJ, Neefe J, Braun TJ, Swinnen LJ, Hersh EM.

J Biol Response Mod. 1990 Dec;9(6):588-91.

PMID:
2074444
30.

Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

Whitehead RP, Ward D, Hemingway L, Hemstreet GP 3rd, Bradley E, Konrad M.

Cancer Res. 1990 Oct 15;50(20):6708-15.

31.

A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study.

Whitehead RP, Earhart RH, Fleming T, Goodman P, Macdonald JS, Pollock T, Ungerleider JS.

Invest New Drugs. 1990 Aug;8(3):295-7.

PMID:
2148743
32.

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.

Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP.

J Natl Cancer Inst. 1990 Jan 17;82(2):143-6.

PMID:
2294224
33.
34.

Recurrent ascites as an unusual complication of chronic pancreatitis.

SCHMIDT ER, WHITEHEAD RP.

JAMA. 1962 May 19;180:533-5. No abstract available.

PMID:
14498703
35.

Marked hypokalemia resulting from percutaneous absorption of fludrocortisone.

WHITEHEAD RP.

Ohio State Med J. 1960 Feb;56:196-7. No abstract available.

PMID:
13844427

Supplemental Content

Loading ...
Support Center